**Question:** Vasopressin antagonist acts on

**Core Concept:** Vasopressin, also known as antidiuretic hormone (ADH), is a peptide hormone produced and released by the hypothalamus that regulates water reabsorption in the kidneys to maintain blood pressure and osmolality. Vasopressin antagonists are medications that block the action of vasopressin, which can be useful in certain clinical scenarios.

**Why the Correct Answer is Right:** Vasopressin antagonists, such as tolvaptan, work by binding to and inhibiting the V2 receptors found in the kidney collecting ducts. These receptors are responsible for the intracellular signal transduction leading to osmoreceptor activation and ultimately, water reabsorption. By blocking these receptors, vasopressin antagonists prevent the activation of osmoreceptors and inhibit water reabsorption, leading to increased urine output and reduced blood osmolality.

**Why Each Wrong Option is Incorrect:**

A. Option A (V1 receptor antagonist) is incorrect because vasopressin primarily acts on V2 receptors, not V1 receptors. V1 receptors are responsible for vasoconstriction, not water reabsorption.

B. Option B (V2 receptor agonist) is incorrect because a true V2 receptor agonist would increase water reabsorption and lead to dehydration. Vasopressin antagonists, like tolvaptan, work in the opposite way, decreasing water reabsorption and promoting diuresis.

C. Option C (V1 receptor agonist) is incorrect as described above – V1 receptors are involved in vasoconstriction, not water reabsorption.

D. Option D (V2 receptor antagonist) is incorrect because a true V2 receptor antagonist would prevent water reabsorption and increase urine output, which is the opposite of what is desired in clinical practice. Vasopressin antagonists, like tolvaptan, are designed to block the effects of vasopressin on V2 receptors, reducing water reabsorption and promoting diuresis.

**Clinical Pearl:** Vasopressin antagonists, like tolvaptan, are used in clinical practice to treat conditions like congestive heart failure, liver cirrhosis, and nephrogenic diabetes insipidus, where excessive water reabsorption caused by high vasopressin levels leads to volume overload and impaired renal function.

In conclusion, vasopressin antagonists are a targeted therapy for conditions involving excessive vasopressin activity, while V1 and V2 receptor agonists and antagonists are not relevant in this context. The correct answer is D, V2 receptor antagonist, as it is the type of receptor targeted by vasopressin antagonists, like tolvaptan, to reduce water reabsorption and increase urine output in specific clinical conditions.